Next Article in Journal
Characterization of a Phospho-Specific Antibody to the Fcε Receptor γ Chain, Reveals Differences in the Regulation of Syk and Akt Phosphorylation
Previous Article in Journal
Antibody-Directed Phototherapy (ADP)
Previous Article in Special Issue
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
Antibodies 2013, 2(2), 306-320; doi:10.3390/antib2020306

Single Domain Antibody Fragments as Drug Surrogates Targeting Protein–Protein Interactions inside Cells

1, 1, 2 and 1,*
1 MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK 2 Dainippon Sumitomo Pharma Co., Ltd., Genomic Science Laboratories, 3-1-98 Kasugade-naka, Konohana-ku, Osaka 544-0022, Japan
* Author to whom correspondence should be addressed.
Received: 3 April 2013 / Revised: 23 April 2013 / Accepted: 24 April 2013 / Published: 2 May 2013
(This article belongs to the Special Issue Single-Domain Antibody)
View Full-Text   |   Download PDF [991 KB, 3 May 2013; original version 2 May 2013]   |  


Many human diseases are caused by mutant or abnormal protein functions that are largely confined to the inside of cells, rather than being displayed on the abnormal cell surface. Furthermore, many of the functional consequences of aberrant proteins, such as in cancer cells, are due to protein–protein interactions (PPIs). Developing reagents that can specifically interfere with PPI is an important goal for both therapeutic use and as reagents to interrogate the functional importance of PPI. Antibody fragments can be used for inhibiting PPI. Our recent technology development has provided a set of simple protocols that allow development of single antibody variable (V) region domains that can function inside the reducing environment of the cell. The heavy chain variable region (VH) segments mainly used in this technology are based on a designer framework that folds inside cells without the need for the intra-chain disulphide bond and can be used as drug surrogates to determine on-target effects (target validation) and as templates for small molecule drug development. In this review, we discuss our work on single domains as intracellular antibodies and where this work might in the future.
Keywords: immunoglobulin; antibody; intracellular; VH; PPI; therapy; macrodrug immunoglobulin; antibody; intracellular; VH; PPI; therapy; macrodrug
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Zeng, J.; Zhang, J.; Tanaka, T.; Rabbitts, T.H. Single Domain Antibody Fragments as Drug Surrogates Targeting Protein–Protein Interactions inside Cells. Antibodies 2013, 2, 306-320.

View more citation formats

Related Articles

Article Metrics


[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert